Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

NBIX Growth Still Looks Strong

Second-quarter 2026 revenues rose 39% year over year to $959 million, while adjusted earnings advanced 73% to $2.85 per share. The results beat the Zacks Consensus Estimate for earnings of $2.26 per share and for revenues of $901.5 million.

The growth outlook remains elevated. Projected 2026 sales growth is 35.8%, while projected EPS growth is 41.9%. Ingrezza remains the main engine, with first-half 2026 sales up 17% to $1.4 billion and full-year guidance raised to $2.825-$2.875 billion.

Neurocrine Diversifies Beyond Ingrezza

Crenessity is becoming a meaningful second growth pillar. First-half 2026 sales reached $337 million, up about 400% year over year and already above the $301 million generated in all of 2025.

Vykat XR adds another rare-disease asset following the Soleno Therapeutics acquisition. It contributed $54 million from May 18 through the end of the second quarter. Management expects launch-related discontinuation effects to largely work through during the third quarter, with sequential sales growth anticipated from the fourth quarter onward.

NBIX Valuation Demands a Closer Look

NBIX trades at a forward 12-month price-to-sales ratio of 3.69, versus 2.02 for its sub-industry and 2.23 for the Medical sector. That premium means investors are already paying for faster growth and successful diversification.

The stock still trades below its five-year median forward sales multiple of 5.18. A forward price-to-earnings ratio of 17.15 and PEG ratio of 0.56 make the valuation picture less one-dimensional, but they do not remove the need for continued execution.

Neurocrine Still Faces Execution Risks

Ingrezza remains the dominant revenue contributor and is exposed to pricing, formulary and policy pressure. Teva Pharmaceutical Industries Ltd. TEVA markets Austedo and Austedo XR for tardive dyskinesia and chorea associated with Huntington's disease, directly overlapping with Ingrezza's approved markets. A lower negotiated Medicare price for Austedo beginning in 2027 could add pressure on Ingrezza.

Vykat XR also carries retention risk, with management expecting a long-term discontinuation rate of 25-30%. Pipeline execution is another concern after recent clinical setbacks. Bristol Myers Squibb Company BMY markets Cobenfy for schizophrenia, adding a newer competitor in a market where Neurocrine is advancing phase III candidate direclidine.

NBIX's Mixed Signals Support a Measured View

For investors weighing buy, hold or wait, NBIX presents a mixed setup. Growth, diversification and a debt-free balance sheet support the long-term story, but the premium sales valuation, Ingrezza dependence and product-development risks reduce the case for ignoring entry discipline.

The stock currently carries a Zacks Rank #3 (Hold). It also has a Growth Score of A, Value Score of B, Momentum Score of D and VGM Score of A. The Style Scores show favorable growth and value characteristics, but the weak Momentum Score and Zacks Rank #3 make the setup more consistent with a hold-or-wait posture than an aggressive buy case.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research